Wardman M, Chintakayala P, Heywood C. The valuation and demand impacts of the worthwhile use of travel time with specific reference to the digital revolution and endogeneity. Transportation. 2019 Oct 23;47:1515-40. doi: 10.1007/s11116-019-10059-x
Damen JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten RJPM, Hooft L, Debray TPA. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 2019 Jun 13;17(1):109. doi: 10.1186/s12916-019-1340-7
Batley R, Bates J, Bliemer M, Borjesson M, Bourdon J, Cabral MO, Chintakayala P, Choudhury C, Daly A, Dekker T, Drivyla E, Fowkes T, Hess S, Heywood C, Johnson D, Laird J, Mackie P, Parkin J, Sanders S, Sheldon R, Wardman M, Worsley T. New appraisal values of travel time saving and reliability in Great Britain. Transportation. 2019 Jun;46:583-621. doi: 10.1007/s11116-017-9798-7
Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, Altman DG, Moons KGM, Hooft L. Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement. BMC Med. 2018 Jul 19;16(1):120. doi: 10.1186/s12916-018-1099-2
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Bristow AL, Wardman M, Chintakayala VPK. International meta-analysis of stated preference studies of transportation noise nuisance. Transportation. 2015;42:71-100. doi: 10.1007/s11116-014-9527-4
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.